Abbott Laboratories' Indian unit has warned of potential supply shortages of two popular laxative syrups after production was prohibited in India's Goa state, where drug inspectors have found lapses at a company factory, a letter shows. Goa, where Abbott has one of its two India plants, asked the company to halt production of Cremaffin and Duphalac syrups last month. The request followed the recall of another Abbott drug which triggered factory inspections by health officials who found contamination risks and sanitisation issues.
Abbott (ABT) closed at $98.93 in the latest trading session, marking a -1.35% move from the prior day.
Abbott (ABT) is set to commercialize several biosimilar molecules in key emerging markets via an expanded collaboration with mAbxience.